mRNA-3705
Sponsors
Moderna Inc., ModernaTX, Inc.
Conditions
Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase DeficiencyMethylmalonic Acidemiaparticipants with isolated methylmalonic acidemia (MMA) due to
methylmalonyl-coenzyme A mutase (MUT) deficiency
Phase 1
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia
Active, not recruitingNCT04899310
Start: 2021-08-06End: 2028-07-01Target: 74Updated: 2026-01-20
An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
RecruitingNCT05295433
Start: 2022-03-08End: 2034-04-02Target: 56Updated: 2025-12-23
A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705.
RecruitingCTIS2022-501997-20-00
Start: 2023-12-01Target: 26Updated: 2025-12-12
A Global, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA-3705 in Participants with Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency
CompletedCTIS2022-502492-32-00
Start: 2023-02-03End: 2025-12-10Target: 30Updated: 2025-12-11